September 14, 2018. The NCHR testifies at the FDA advisory board committee for tobacco products regarding advertisements that target the youth.
Read More »On Medical Treatments & Products
NCHR Testimony on Pediatric Advisory Committee Meeting for Drugs Lexapro, Intuniv, and Desferasirox
September 20, 2018. NCHR Testimony on Pediatric Advisory Committee Meeting for drugs Lexapro, Intuniv and Desferasirox. This meeting was to go over the safety profiles of the aforementioned drugs, label profiles as well as recent clinical studies done.
Read More »Summary of Published Study by MD Anderson Physicians on the Increase in Rare Diseases Among Women with Breast Implants
September 17, 2018. We summarize the study conducted by MD Anderson Cancer Center regarding the incidence of rare diseases among women with breast implants.
Read More »NCHR Testimony on Amikacin Liposome Inhalation Suspension (ALIS) in Nontubercuolous Mycobacterial (NTM) Lung Disease
August 7, 2018. NCHR testimony of Amikacin Liposome Inhalation Suspension in Nontubercuolous Mycobacterial Lung Disease in regards to safety and efficacy.
Read More »NCHR Testimony on Omadacycline for Skin Infections and Pneumonia
August 8, 2018. If omadacycline is no better than some drugs on the market, and may be less safe or less effective for older patients, those with more serious infections, and patients with diabetes and lung disease, it is important to conduct further studies to know whether they should be excluded from the indication or not.
Read More »